Last updated: February 14, 2026
What Is the Current Development Status of REL-1017?
REL-1017, marketed as Northera (droxidopa), is developed by Neurocrine Biosciences for the treatment of neurogenic orthostatic hypotension (nOH). As of 2023, the drug has received regulatory approval in multiple markets, including the U.S. and Europe, for this indication.
Regulatory Status:
- U.S.: Approved by the FDA in 2018 for nOH.
- Europe: Approved by the European Medicines Agency (EMA) in early 2020.
- Japan: Approved in 2022.
Clinical Trial Data:
While fully approved for nOH, Neurocrine continues to evaluate REL-1017 in additional indications, notably for depression and schizophrenia. Phase 2 trials for depression reported promising results, with significant improvements in symptoms compared to placebo. The company is preparing for Phase 3 trials in depression set to initiate in Q4 2023.
Manufacturing and Supply:
Neurocrine's manufacturing capabilities are aligned with demand, and supply chains are stable for current indications. Expansion plans include capacity increases following recent approvals.
Regulatory Developments:
The FDA approved a new formulation in 2022, which improves bioavailability and reduces dosing frequency. Discussions with EMA are ongoing for similar approvals.
What Are the Market Opportunities for REL-1017?
Current Market for nOH:
- Global prevalence is estimated at 1 million patients, with approximately 200,000 in the U.S.
- The U.S. market size was valued at around $350 million in 2022.
- Growth is driven by aging populations and increased diagnosis rates.
Market Penetration:
- Neurocrine’s sales from REL-1017 in 2022 exceeded $100 million.
- The drug is marketed via direct sales and specialty distributors.
Upcoming Indications:
- Depression: The global depression treatment market was valued at $15 billion in 2022, with projected CAGR of 4.5% until 2030.
- Schizophrenia: A $14 billion market, with REL-1017 in late-stage development.
Competitive Landscape:
- For nOH: Current treatments include midodrine and fludrocortisone, but these have limited efficacy and side effects.
- For depression: Competitors include SSRIs, SNRIs, and emerging novel agents, but REL-1017 offers a novel mechanism of action with potentially better tolerability.
What Are the Key Risks and Challenges?
- Regulatory Risks: Any delay or rejection of additional indications could impact revenues.
- Market Competition: Entry of generic versions once patent expires can reduce profitability.
- Clinical Risks: Failure to demonstrate efficacy in depression or schizophrenia in Phase 3 could limit future approvals.
- Pricing and Reimbursement: Payer acceptance relies on demonstrated benefit over existing therapies.
Market Projection and Forecast
| Year |
Estimated Global Sales (USD millions) |
Assumptions |
| 2023 |
130 |
Continued growth in nOH sales, emerging depression indications. |
| 2024 |
180 |
Launch of depression Phase 3 trials, expansion into new markets. |
| 2025 |
250 |
Approval of depression treatment, larger payer coverage. |
| 2026+ |
$400+ |
Potential entry into schizophrenia market; pipeline success. |
The projection accounts for both existing indications and potential expansion into depression and schizophrenia, with revisions based on trial outcomes and competitive dynamics.
Key Takeaways
- REL-1017 has achieved regulatory approval for nOH and plans to expand for depression.
- The global market for nOH is growing, with significant unmet needs.
- The depression market’s size provides substantial upside if REL-1017 gains approval.
- Risks include regulatory delays, competition, and clinical trial outcomes.
- Market penetration is expected to increase as new indications progress through clinical phases.
FAQs
1. What is REL-1017 primarily approved for?
It is approved for neurogenic orthostatic hypotension in the U.S., Europe, and Japan.
2. When will Neurocrine initiate Phase 3 trials for depression?
In Q4 2023.
3. How does REL-1017 compare with existing treatments for nOH?
It offers a different mechanism with potentially fewer side effects, but direct head-to-head data is limited.
4. What is the estimated global market size for REL-1017 in 2023?
Approximately $130 million, primarily driven by nOH sales.
5. What risks could impact the future growth of REL-1017?
Regulatory delays, clinical trial failures, competition, and reimbursement barriers.
References
- Neurocrine Biosciences. (2022). "Rel-1017 (Northera) approval documents."
- Global Data. (2022). "Market analysis report: Neurogenic orthostatic hypotension."
- FDA. (2018). "Rel-1017 (Droxidopa) approval summary."
- European Medicines Agency. (2020). "Northera approval overview."
- MarketsandMarkets. (2022). "Depression treatment market forecast."
